Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR
Therapeutic Apheresis and Dialysis · 14.07.2026
DOI: 10.1002/1744-9987.70188 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 14.07.2026. Verfasst von Ryo Takaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Whether cell‐free and concentrated ascites reinfusion therapy (CART) improves renal function remains unclear. We investigated the effects of CART on renal function.
Methods
We retrospectively analyzed changes in renal function after CART in 157 patients (264 sessions) with or without chronic kidney disease (CKD) who underwent the treatment between June 1, 2010, and March 31, 2022.
Results
The most common underlying disease was malignant ascites (93.6%), most frequently caused by breast ( n = 49, 31.2%) and ovarian ( n = 31, 19.7%) cancers. The mean patient age was 61.6 ± 12.2 years (women, 82.1%). The median processed ascites volume was 4.26 [3.40–6.43] L, and the mean number of CART sessions per patient was 1.66 ± 1.38. No severe adverse events were observed. The estimated glomerular filtration rate (eGFR) significantly increased after CART (from 64.5 [47.5–82.9] to 65.1 [50.5–85.6] mL/min/1.73 m 2 ; p = 0.004), particularly in patients with CKD stage G3b and G4 (G3b: from 35.4 [33.0–38.6] to 45.9 [36.1–52.5] mL/min/1.73 m 2 ; p = 0.005, G4: from 25.1 [21.0–26.8] to 27.3 [21.1–35.3] mL/min/1.73 m 2 ; p = 0.045).
Conclusion
CART may be associated with an increase in eGFR, particularly in patients with CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
- Department of Internal Medicine, Division of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
- Kojima Kidney and Dialysis Clinic, Yokohama, Kanagawa, Japan.
- Department of Internal Medicine, Division of Nephrology, Nagasaki University Hospital, Nagasaki, Japan.
ORCID-Profile: Ryo Takaki, Shigeki Kojima, Tomoya Nishino
Zitieren
APA
Takaki, R., Kohatsu, K., Kojima, S., Shibagaki, Y., Nishino, T., & Sakurada, T. (2026). Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR. Therapeutic Apheresis and Dialysis. https://doi.org/10.1002/1744-9987.70188
Vancouver
Takaki R, Kohatsu K, Kojima S, Shibagaki Y, Nishino T, Sakurada T. Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR. Therapeutic Apheresis and Dialysis. 2026. doi:10.1002/1744-9987.70188
BibTeX
@article{Takaki2026,
author = {Takaki, Ryo and Kohatsu, Kaori and Kojima, Shigeki and Shibagaki, Yugo and Nishino, Tomoya and Sakurada, Tsutomu},
title = {Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR},
journal = {Therapeutic Apheresis and Dialysis},
year = {2026},
doi = {10.1002/1744-9987.70188}
}
EUVIMED